Wheelchair-Bound Patient With Rare Metastatic Neck Tumor Has Exceptional Response to Peptide Radiation Therapy — Twice

What the researchers found

A 45-year-old woman with metastatic carotid body tumor showed an excellent initial response to 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT). After disease progression with widespread metastases and spinal cord compression at multiple levels leaving her wheelchair-bound, rechallenge PRRT again produced an exceptional treatment response. This case demonstrates that retreatment with peptide-targeted radiation can be effective in somatostatin receptor-expressing paragangliomas.

Why it matters

Metastatic head and neck paragangliomas have very limited treatment options. This case demonstrates that peptide receptor radionuclide therapy — which specifically targets tumor cells using a somatostatin peptide analogue carrying a radioactive payload — can work not just once but twice in the same patient. This is important for clinicians managing these rare tumors who need to know that retreatment is a viable option.

How the study worked

This is a clinical case report of a single patient treated at a medical center. The patient was evaluated with imaging showing somatostatin receptor-expressing metastatic lesions, treated with 177Lu-DOTATATE PRRT initially with good response, then retreated upon disease recurrence. Treatment response was assessed clinically and with imaging.

What this study cannot tell us

This is a single case report, representing the lowest level of clinical evidence. Individual responses cannot be generalized to all patients with metastatic paragangliomas. Long-term outcomes, cumulative radiation safety, and specific imaging response details are not provided in the abstract. The rarity of metastatic carotid body tumors makes it difficult to study systematically.

How to read the evidence

This is a single case report, the lowest level of clinical evidence. While the exceptional response to retreatment is noteworthy, individual cases cannot establish treatment efficacy for the broader patient population.

When this study was published

Published in 2026, this is a very recent case report demonstrating the ongoing use and evolution of peptide receptor radionuclide therapy for rare tumors.

The bigger picture

Peptide receptor radionuclide therapy represents a precision medicine approach where peptides serve as targeting missiles to deliver radiation directly to tumor cells. This case adds to the growing evidence that PRRT retreatment is feasible and effective, particularly important for rare tumors where treatment evidence is limited. As PRRT is increasingly used for neuroendocrine tumors, understanding retreatment potential broadens its clinical utility.

Questions still open

• How many cycles of PRRT rechallenge can be safely administered, and what are the cumulative toxicity limits?
• What proportion of paraganglioma patients maintain somatostatin receptor expression after initial PRRT?
• Could PRRT be combined with other therapies for even better outcomes in metastatic paragangliomas?

Common questions

Read the original research

Exceptional Response to Rechallenge Peptide Receptor Radionuclide Therapy in Metastatic Carotid Body Tumor.

Clinical nuclear medicine, 51(1), e52-e54

Citation

Aggarwal, Piyush; Satapathy, Swayamjeet; Sarungbam, Bidya; Sood, Ashwani; Kumar, Rajender; Goyal, Shikha; Mittal, Bhagwant Rai. (2026). Exceptional Response to Rechallenge Peptide Receptor Radionuclide Therapy in Metastatic Carotid Body Tumor.. Clinical nuclear medicine, 51(1), e52-e54. https://doi.org/10.1097/RLU.0000000000005930